pulmonx corp - LUNG

LUNG

Close Chg Chg %
2.08 -0.03 -1.39%

Open Market

2.05

-0.03 (1.39%)

Volume: 75.50K

Last Updated:

Sep 9, 2026, 10:33 AM EDT

Company Overview: pulmonx corp - LUNG

LUNG Key Data

Open

$2.12

Day Range

2.04 - 2.16

52 Week Range

1.13 - 2.89

Market Cap

$94.92M

Shares Outstanding

42.95M

Public Float

38.37M

Beta

0.34

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.16

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

473.42K

 

LUNG Performance

1 Week
 
-5.88%
 
1 Month
 
1.96%
 
3 Months
 
51.82%
 
1 Year
 
22.35%
 
5 Years
 
-94.64%
 

LUNG Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About pulmonx corp - LUNG

Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. It operates through the following geographical segments: United States, Europe, Middle East, Africa, Asia Pacific, and Other International. The company was founded by Rodney Perkins on December 26, 1995 and is headquartered in Redwood City, CA.

LUNG At a Glance

Pulmonx Corp.
700 Chesapeake Drive
Redwood City, California 94063
Phone 1-650-364-0400 Revenue 90.50M
Industry Medical Specialties Net Income -54,003,000.00
Sector Health Technology 2025 Sales Growth 8.006%
Fiscal Year-end 12 / 2026 Employees 296
View SEC Filings

LUNG Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.994
Price to Book Ratio 1.702
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.453
Enterprise Value to Sales 0.843
Total Debt to Enterprise Value 0.739

LUNG Efficiency

Revenue/Employee 305,733.108
Income Per Employee -182,442.568
Receivables Turnover 7.147
Total Asset Turnover 0.60

LUNG Liquidity

Current Ratio 5.06
Quick Ratio 4.27
Cash Ratio 3.49

LUNG Profitability

Gross Margin 74.079
Operating Margin -59.298
Pretax Margin -58.982
Net Margin -59.674
Return on Assets -35.804
Return on Equity -77.188
Return on Total Capital -48.88
Return on Invested Capital -43.641

LUNG Capital Structure

Total Debt to Total Equity 104.154
Total Debt to Total Capital 51.017
Total Debt to Total Assets 42.077
Long-Term Debt to Equity 101.722
Long-Term Debt to Total Capital 49.826
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Pulmonx Corp - LUNG

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
53.66M 68.67M 83.79M 90.50M
Sales Growth
+10.84% +27.98% +22.01% +8.01%
Cost of Goods Sold (COGS) incl D&A
13.80M 18.32M 21.89M 23.46M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.00M 1.95M 1.59M 1.15M
Depreciation
3.90M 1.45M 1.39M 1.05M
Amortization of Intangibles
- 100.00K 100.00K 100.00K
COGS Growth
+7.91% +32.80% +19.46% +7.17%
Gross Income
39.87M 50.35M 61.90M 67.04M
Gross Income Growth
+11.89% +26.31% +22.94% +8.30%
Gross Profit Margin
+74.29% +73.32% +73.88% +74.08%
2022 2023 2024 2025 5-year trend
SG&A Expense
98.50M 112.29M 117.89M 120.70M
Research & Development
15.40M 18.08M 15.85M 19.49M
Other SG&A
83.11M 94.21M 102.03M 101.21M
SGA Growth
+18.77% +13.99% +4.99% +2.39%
Other Operating Expense
- - - -
-
Unusual Expense
- - - 1.72M
-
EBIT after Unusual Expense
(58.64M) (61.94M) (57.70M) (53.66M)
Non Operating Income/Expense
1.13M 4.89M 5.32M 3.44M
Non-Operating Interest Income
1.53M 5.57M 5.06M 2.65M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.07M 3.23M 3.51M 3.15M
Interest Expense Growth
+28.59% +203.19% +8.51% -10.04%
Gross Interest Expense
1.07M 3.23M 3.51M 3.15M
Interest Capitalized
- - - -
-
Pretax Income
(58.57M) (60.27M) (55.89M) (53.38M)
Pretax Income Growth
-21.22% -2.91% +7.26% +4.50%
Pretax Margin
-109.15% -87.76% -66.71% -58.98%
Income Tax
353.00K 571.00K 500.00K 626.00K
Income Tax - Current - Domestic
66.00K 62.00K 53.00K 45.00K
Income Tax - Current - Foreign
232.00K 483.00K 471.00K 600.00K
Income Tax - Deferred - Domestic
- 46.00K 17.00K 15.00K
Income Tax - Deferred - Foreign
9.00K 9.00K (39.00K) (19.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(58.92M) (60.84M) (56.39M) (54.00M)
Minority Interest Expense
- - - -
-
Net Income
(58.92M) (60.84M) (56.39M) (54.00M)
Net Income Growth
-21.09% -3.26% +7.31% +4.24%
Net Margin Growth
-109.80% -88.60% -67.30% -59.67%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(58.92M) (60.84M) (56.39M) (54.00M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(58.92M) (60.84M) (56.39M) (54.00M)
EPS (Basic)
-1.5884 -1.6022 -1.4419 -1.3273
EPS (Basic) Growth
-17.93% -0.87% +10.00% +7.95%
Basic Shares Outstanding
37.10M 37.97M 39.11M 40.69M
EPS (Diluted)
-1.5884 -1.6022 -1.4419 -1.3273
EPS (Diluted) Growth
-17.93% -0.87% +10.00% +7.95%
Diluted Shares Outstanding
37.10M 37.97M 39.11M 40.69M
EBITDA
(54.64M) (59.99M) (54.39M) (52.51M)
EBITDA Growth
-23.77% -9.79% +9.32% +3.47%
EBITDA Margin
-101.82% -87.35% -64.92% -58.02%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 5.167
Number of Ratings 5 Current Quarters Estimate -0.257
FY Report Date 09 / 2026 Current Year's Estimate -1.044
Last Quarter’s Earnings -0.24 Median PE on CY Estimate N/A
Year Ago Earnings -1.33 Next Fiscal Year Estimate -0.942
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 5 5
Mean Estimate -0.26 -0.22 -1.04 -0.94
High Estimates -0.23 -0.17 -0.97 -0.80
Low Estimate -0.28 -0.24 -1.09 -1.08
Coefficient of Variance -7.00 -12.96 -4.26 -10.89

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 3
OVERWEIGHT 0 0 0
HOLD 2 2 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Pulmonx Corp in the News